ClinicalTrials.gg
Not yet recruitingNCT07885917HARBORUpdated Oct 21, 2026

Long-Term Safety and Tolerability of Nizubaglustat in Participants With Rare Lysosomal Disorders

A Phase 2/3 interventional study of AZ-3102 in Niemann-Pick Disease Type C, GM2 Gangliosidosis and GM1 Gangliosidosis, sponsored by Azafaros B.V.. Not yet recruiting. Open to participants aged 4 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Azafaros B.V. · Phase 2/3, Interventional, and Treatment

Updated Oct 21, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
218
Allocation
Not applicable
Ages
4 Years and older
Sex
All
01

Study summary

This is an open-label extension trial to evaluate the long-term safety and tolerability of nizubaglustat (AZ-3102) in participants with rare lysosomal disorders who have participated in a previous nizubaglustat trial and wish to continue nizubaglustat treatment.

Read the detailed description

This is a multi-center, global, open-label, extension trial in participants with Niemann-Pick disease type C (NPC), GM1 gangliosidosis, GM2 gangliosidosis, or Gaucher disease type 3 (GD3) who previously participated in a clinical trial of nizubaglustat (AZ-3102) and wish to continue treatment. All participants will receive nizubaglustat once daily.

The primary objective is to assess the long-term safety and tolerability of continued daily administration of nizubaglustat. The trial will also investigate the effect of nizubaglustat on disease biomarkers and explore the effect of long-term treatment on neurological aspects of disease progression.

Participants may remain in the trial under marketing authorization has been granted for nizubaglustat in their country or until the sponsor decides to stop the trial.

02

Conditions studied

  • Niemann-Pick Disease Type C
  • GM2 Gangliosidosis
  • GM1 Gangliosidosis
  • Gaucher Disease Type 3

Keywords

  • NPC
  • GM1
  • GM2
  • GD3
  • Nizubaglustat
  • HARBOR
  • Rare Lysosomal Disorders
  • AZ-3102
  • GM1 gangliosidosis
  • GM2 gangliosidosis
  • Gaucher Disease Type 3
  • Niemann-Pick disease type C
03

In context

Niemann-Pick Disease, Type C

37 studies on the registry are indexed under Niemann-Pick Disease, Type C; 8 are open to participants now.

This study's planned enrollment of 218 is above the median of 21 across 27 interventional studies indexed under Niemann-Pick Disease, Type C.

Browse Niemann-Pick Disease, Type C studies →

Lead sponsor

Azafaros B.V. is the lead sponsor of 8 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
4 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have participated in a trial of nizubaglustat and wish to continue nizubaglustat treatment
  • Participation is considered beneficial by the investigator
  • Female participants of who are willing to follow the protocol-defined requirements
  • Male participants who are willing to follow the protocol-defined contraceptive requirements

Exclusion criteria

Exclusion Criteria:

  • A positive serum pregnancy test (for women of ).
  • Any medical event or condition that prevents participation in the trial based on the judgment of the investigator (e.g., severe infection and severe cognitive impairment).
  • Use of any other treatment with a similar mode of action to nizubaglustat (GCS or NLGase inhibition), e.g., miglustat or venglustat.
  • Participation in another interventional trial or non-interventional study or in an Early Access Program.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
218 participants (estimated)

Study arms

  • Experimental
    All participants will receive nizubaglustat

    Drug: AZ-3102

Interventions

  • Daily oral intake of nizubaglustat (AZ-3102) dispersible tablets

06

What researchers measure

Primary outcomes

  1. The Incidence and severity of treatment-emergent adverse events (TEAEs)

    Change in vital signs parameters over time

    Time frame: Through study completion, an average of 4 years

  2. The Incidence and severity of treatment-emergent adverse events (TEAEs)

    Change in laboratory safety parameters over time.

    Time frame: Through study completion, an average of 4 years

Secondary outcomes

  1. Change in concentrations

    Absolute and percent change in the concentrations of Plasma lyso-monosialoganglioside GM1 (Lyso-GM1; for participants with GM1) since the first dose of nizubaglustat

    Time frame: Through study completion, an average of 4 years

  2. Change in concentrations

    Absolute and percent change in the concentrations of Plasma Lyso-GM2 (for participants with GM2) since the first dose of nizubaglustat

    Time frame: Through study completion, an average of 4 years

  3. Change in concentrations

    Absolute and percent change in the concentrations of Plasma N-palmitoyl-O-phosphocholine-serine (PPCS; for participants with NPC) since the first dose of nizubaglustat

    Time frame: Through study completion, an average of 4 years

  4. Change in concentrations

    Absolute and percent change in the concentrations of Glucosylsphingosine (GlcSph; for participants with GD3) since the first dose of nizubaglustat

    Time frame: Through study completion, an average of 4 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Apr 2030, 39 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2026
First posted
Oct 21, 2026
StartEst.
Dec 10, 2026
Primary completionEst.
Apr 1, 2030
CompletionEst.
Apr 1, 2030
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07885917
Lead sponsor
Azafaros B.V.
Responsible party
Sponsor
First posted
Oct 21, 2026
Start date
Dec 10, 2026 (estimated)
Primary completion
Apr 1, 2030 (estimated)
Completion
Apr 1, 2030 (estimated)
Last update
Oct 21, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nizubaglustat

Start the discussion